Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes

類似資料

• MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D
  著者:: Inzucchi, Silvio E, 等
  出版事項: (2020)
• Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
  著者:: Ceriello, Antonio, 等
  出版事項: (2020)
• Slope of change in HbA(1c) from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes
  著者:: DeFronzo, Ralph A., 等
  出版事項: (2018)
• Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial
  著者:: Fitchett, David, 等
  出版事項: (2020)
• Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
  著者:: Inzucchi, Silvio E, 等
  出版事項: (2020)